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Oral cancer is the sixth most common cancer type in the world, and 90% of it is
represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive
and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes
of high morbidity and mortality; indeed the majority of OSCC has been lately identified in
the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences
and/or metastases are found in more than half of the patients (80% of cases within
the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a
serious issue for public health. Currently, histological investigation represents the “gold
standard” of OSCC diagnosis; however, recent studies have evaluated the potential
use of non-invasive methods, such as “liquid biopsy,” for the detection of diagnostic
and prognostic biomarkers in body fluids of oral cancer patients. Saliva is a biofluid
containing factors such as cytokines, DNA and RNA molecules, circulating and tissue-
derived cells, and extracellular vesicles (EVs) that may be used as biomarkers; their
analysis may give us useful information to do early diagnosis of OSCC and improve
the prognosis. Therefore, the aim of this review is reporting the most recent data
on saliva biomarker detection in saliva liquid biopsy from oral cancer patients, with
particular attention to circulating tumor DNA (ctDNA), EVs, and microRNAs (miRNAs).
Our results highlight that saliva liquid biopsy has several promising clinical uses in OSCC
management; it is painless, accessible, and low cost and represents a very helpful
source of diagnostic and prognostic biomarker detection. Even if standardized protocols
for isolation, characterization, and evaluation are needed, recent data suggest that saliva
may be successfully included in future clinical diagnostic processes, with a considerable
impact on early treatment strategies and a favorable outcome.
Keywords: liquid biopsy, salivary biomarkers, circulating tumor DNA, extracellular vesicles, microRNAs, early
diagnosis, prognosis, oral squamous cell carcinoma
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INTRODUCTION
Oral cancer is one of the most common cancers in the world,
representing a serious problem for global health (Shah and Gil,
2009). Roughly 90% of oral cancers histologically originate from
squamous cells and are classified as oral squamous cell carcinoma
(OSCC) (Rivera, 2015; Mascitti et al., 2018).
Despite current advancements in cancer prevention strategies
and therapeutic approaches, the prognosis of OSCC-affected
patients is still poor; this mainly depends on late diagnosis in
an advanced stage (i.e., III or IV) (Rivera, 2015; Mascitti et al.,
2018). Moreover, after primary treatment, recurrences and/or
metastases are found in more than half of the patients (80%
of cases within the first 2 years), and the 5-year survival rate
is still lower than 50%, resulting in a serious issue for public
health; as a result, in the latest decades, the annual mortality rate
has remained unchanged at 145,000 cases (Grobe et al., 2013;
Panzarella et al., 2014; Rivera, 2015).
To date, the “gold standard” for OSCC diagnosis is
represented by a clinical oral examination integrated by a
histological investigation on tissue biopsy of suspicious lesions
(Fuller et al., 2015). However, cancer research is currently
focusing on finding less invasive and cost-effective methods to
provide a more comprehensive view of the cancer profile, also
to more easily monitor its evolution and therapeutic response
(Siravegna et al., 2017; Wang J. et al., 2017). In this regard,
many non-invasive techniques such as liquid biopsy have been
recently proposed as supportive tools for diagnosis, prognosis,
and follow-up of OSCC (Dionne et al., 2015; Fuller et al., 2015;
Aro et al., 2017).
As is widely known, cancers developed from different
types of DNA alterations which are classified based on their
effects on structure: small-scale genetic alterations, which
comprise different types of point mutations (e.g., DNA
base insertions, substitutions, and deletions), and large-scale
gene alterations such as DNA rearrangements (e.g., gene
duplications/deletions, chromosomal translocations/inversions,
and loss of heterozygosity) (Stadler et al., 2010). It is noteworthy
that the changes in DNA genetic and epigenetic structure (i.e.,
altered function of factors implicated in gene expression) can be
detected by several biomarkers as circulating tumor cells (CTCs),
circulating tumor DNA (ctDNA), microRNAs (miRNAs), and
extracellular vesicles (EVs), which can be found in several
biological fluids such as blood, serum, plasma, pleural fluid, urine,
and saliva (Kaczor-Urbanowicz et al., 2017). The evaluation of
these cancer biomarkers in liquid biopsy has the advantage of
providing a real-time picture of primary and metastatic tumors
at different time points, giving information about tumor and
tumor burden and early evidence of drug resistance and tumor
recurrence (Di Meo et al., 2017). Moreover, liquid biopsy analysis
allows defining of the DNA molecular profile of cancer patients,
whose inclusion in the tumor, node, and metastasis staging
system may help to develop more highly personalized therapies
and decrease risks of inappropriate treatments (Xu et al., 2017).
Oral squamous cell carcinoma is strictly associated with the
oral microenvironment, resulting in a direct contact with saliva,
an acidic biological fluid derived from secretion of major and
minor salivary glands, and involved in many physiological and
pathological processes (Kaufman and Lamster, 2002; Nieuw
Amerongen and Veerman, 2002; Chiappin et al., 2007; Jankowska
et al., 2007; Lee and Wong, 2009). In recent decades, saliva
has been widely investigated as a promising source of OSCC
biomarkers for liquid biopsy (Kaczor-Urbanowicz et al., 2017).
Employing saliva in liquid biopsy for OSCC management has
many advantages over other specimens: (i) it is considered “the
mirror of the body,” reflecting any physiological and pathological
change on local and distant sites of the body; (ii) it represents
an easier, quicker, and more accessible screening tool (Kaczor-
Urbanowicz et al., 2017); and (iii) it gives the opportunity to
collect larger volumes of samples for examination, to easily repeat
analysis, and to monitor OSCC over time (Kaczor-Urbanowicz
et al., 2017; Gai et al., 2018; Khurshid et al., 2018).
In light of the above, this narrative review aims to describe
the recent data regarding the employment of different salivary
biomarkers in liquid biopsy for OSCC diagnosis, prognosis,
follow-up, and patient response to therapy. Moreover, we discuss
the current challenges and future perspectives concerning the use
of salivary biomarkers in OSCC management.
SALIVARY BIOMARKERS AND OSCC
Circulating Tumor DNA
During physiological cellular turnover or in particular
pathological conditions, apoptotic and necrotic cells release
debris and DNA/RNA molecules into body fluids. In physiologic
conditions, cell-derived molecules and debris are removed by
phagocytes; instead, in cancer patients, this mechanism results
in impairment, inducing the accumulation of cell-free DNA
(cfDNA) in the tissue microenvironment and biological fluids
(Jahr et al., 2001; Chan et al., 2004; Mouliere et al., 2011). As a
result, cancer patients have increased levels of cfDNA in body
fluids (Diehl et al., 2008; Kohler et al., 2011). cfDNA released from
cancer cells, also known as ctDNA, can be distinguished from
cfDNA physiologically released from non-cancer cells through
several features: biofluid concentration, somatic mutations, and
overall size. Because of random partial digestion of genomic
DNA, cfDNA from apoptotic cells is measured at 180–200 base
pairs; necrosis or autophagy during the cancer process usually
generates larger DNA molecules, from 100 to 400 base pairs
(Wang et al., 2003; Diehl et al., 2008; Kohler et al., 2011).
It is noteworthy that many studies also showed that ctDNA
in cancer patients reflects the genetic and epigenetic alterations
found in tissue samples of malignant lesions (Ignatiadis et al.,
2015; Cheng et al., 2016; Qin et al., 2016); in addition, many
other cancer characteristics such as size, cellular turnover,
stage, vascularity, and drug response are associated with ctDNA
concentrations (Chang et al., 2017).
Several mechanisms have been suggested to explain the release
of ctDNA in body fluids of cancer patients, even if they remain
dubious. It could be the result of accelerated metabolism of cancer
cells, responsible for the increased number of apoptotic/necrotic
cells (Shukla et al., 2013; Francis and Stein, 2015; Volik et al.,
2016; Payne et al., 2018). Cancer cells released from primary
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tumor mass and disseminating throughout body fluids (e.g.,
CTCs) could actively release fragments of cellular nucleic
acids, which, when internalized from non-cancer cells, induce
neoplastic transformation (Ilie et al., 2014; Cheng et al., 2016).
Cancer transformation can be also the result of the internalization
of vesicles (e.g., EVs), containing ctDNA and actively released
from cancer cells, from healthy cells (Lau et al., 2013; Kaczor-
Urbanowicz et al., 2017).
ctDNA is mainly released into the bloodstream; however,
it can also be found in other body fluids. For instance, by
means of salivary gland ultrafiltration, passive diffusion, or active
transport, ctDNA can easily reach saliva from a local site and
bloodstream, carrying information regarding primary tumors
and/or metastasis (Pu et al., 2016; Kaczor-Urbanowicz et al., 2017;
Wang X. et al., 2017). Thanks to less dilution and contamination,
the analysis of the ctDNA in saliva is much more sensitive than
that in the bloodstream (Peng et al., 2017).
As described in Table 1, many studies have applied salivary
ctDNA in the management of head and neck squamous cell
carcinoma (HNSCC) (Liao et al., 2000; El-Naggar et al., 2001;
Viet and Schmidt, 2008; Sethi et al., 2009; Demokan et al., 2010;
Carvalho et al., 2011; Guerrero-Preston et al., 2011; Sun et al.,
2012; Rettori et al., 2013; Ramadoss et al., 2015; Wang et al.,
2015; Ferlazzo et al., 2017; Lacombe et al., 2017). When HNSCC
patients with tumors at the oral cavity, oropharynx, larynx, and
hypopharynx were enrolled at the early stages (I and II) and
late stages (III and IV), ctDNA was detected, respectively, in
100% of HNSCC patients enrolled at the early stages and in
95% enrolled at the late stages, with an enrichment in saliva
of all patients affected by OSCC; this result is very specific for
OSCC detection. Moreover, being postsurgically found in 100%
of patients who subsequently had a clinical recurrence and in
any patients without recurrence, it could be also a valuable
biomarker for oral cancer follow-up and surveillance (Wang
et al., 2015). Interestingly, when the OSCC-leading genetic
alterations in ctDNA of saliva and tissue samples were analyzed,
a correlation in loss of heterozygosity and p53 mutations was
found, demonstrating that saliva can be a reliable and non-
invasive alternative to tissue biopsy for OSCC detection (Liao
et al., 2000; El-Naggar et al., 2001; Ramadoss et al., 2015).
Among the epigenetic alterations frequently found in salivary
ctDNA, gene promoter methylation has been extensively
investigated in cancer. Numerous studies, comparing the
methylation rate of genes involved in the cell cycle, proliferation,
and apoptosis, found a difference in salivary samples of HNSCC
patients and healthy subjects, demonstrating that salivary ctDNA
methylation could be considered a very promising biomarker
for HNSCC management and specifically OSCC diagnosis,
prognosis, and follow-up (Viet et al., 2007; Viet and Schmidt,
2008; Sethi et al., 2009; Puttipanyalears et al., 2014). Epigenetic
alterations such as DNA methylation rate can be easily detected
in salivary ctDNA, proving to be a valuable sensitive and specific
marker for OSCC diagnosis and prognosis (Demokan et al., 2010;
Pattani et al., 2010; Guerrero-Preston et al., 2011; Ferlazzo et al.,
2017). Moreover, the evaluation of the methylation status of
genes, involved in OSCC development at diagnosis, seems to be
useful as a predictive factor to develop a personalized therapy and
assess the patient response during surveillance (Viet and Schmidt,
2008; Lacombe et al., 2017).
Extracellular Vesicles
As is widely known, EVs represent one of the main mechanisms
of intercellular communication (Deutsch et al., 2008). The
discovery of cell-derived EVs in saliva able to selectively
“package” factors such as DNAs, RNAs, miRNAs, and proteins
recently attracted the attention of researchers, being promising
additional sources of biomarkers (Valadi et al., 2007; Krief et al.,
2011; El Andaloussi et al., 2013; Lötvall et al., 2014; Wong,
2015; Yáñez-Mó et al., 2015). To date, the most investigated
vesicles in cancer development and progression are exosomes and
microvesicles, small membrane vesicles similar in some structural
and functional elements but distinguished by means of size and
cellular release processes (Wong, 2006; Pfaffe et al., 2011; Corrado
et al., 2013; Kastelowitz and Yin, 2014).
Many studies demonstrated that EVs, transferring protein
and nucleic acids able to support or inhibit tumorigenesis, are
implicated in tumor microenvironments (Kalluri, 2016; Ruivo
et al., 2017); additionally, it has been recently shown that EVs
may have a role in oral cancers (Gai et al., 2018; Han et al.,
2018). Differences in relative size, proteome signature, and
expression of exosomal markers have been highlighted between
OSCC parental and metastatic cells; moreover, OSCC parental
cells release exosomes with oncogenic markers able to influence
the surrounding tumor microenvironment. The evaluation of
exosomal markers from OSCC patients can support diagnosis,
prognosis, and assessment of patient response to therapy,
detecting potential tumor recurrence (Byun et al., 2015; Languino
et al., 2016; Li et al., 2016; Liu et al., 2017; Ono et al., 2018).
Nevertheless, few studies have evaluated the role of salivary
EVs in OSCC management (Table 2; Winck et al., 2015;
Zlotogorski-Hurvitz et al., 2016). Salivary tumor-derived
exosomes have different morphological and molecular features
compared to healthy saliva samples and can detect cancer
and malignant transformations early in high-risk patients
(Zlotogorski-Hurvitz et al., 2016; Malonek et al., 2018). In the
comparison of the proteomic analysis of whole saliva from
healthy and OSCC patients, it was also shown that the qualitative
and quantitative features of saliva EVs may support OSCC
diagnosis and give information regarding the prognosis of cancer
patients. The proteome of salivary EVs shows the presence of
proteins implicated in cancer inflammatory response, transport
of metals, and cellular growth and proliferation, allowing
the classification of OSCC patients and the ability to give
prognosis information with a high percentage of accuracy
(Winck et al., 2015).
MicroRNAs
MicroRNAs are small single-strand RNA molecules (19–21
nucleotides), transcribed by cellular polymerase RNA and
submitted to a double sequential cut: in the nucleus (primary
miRNA) and cytoplasm (precursor miRNA). Then, depending on
the complementarity level with the target, they cleave a messenger
RNA (mRNA) or inhibit its translation (Bartel, 2004; Perron and
Provost, 2008).
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TABLE 1 | Diagnostic, prognostic, and follow-up applications of ctDNA in OSCC, based on population study.
Authors
(year)
Title Cases Controls Type of
alteration
Application Results
Liao et al.,
2000
Mutation of p53 gene codon 63 in
saliva as a molecular marker for oral
squamous cell carcinomas
10 OSCC 27 DNA point
mutation
Diagnosis Of the OSCCs, 62.5% harbor C-deletion in exon 4 codon
63 from preoperative saliva samples. TSG p53 exon 4
codon 63 mutation is a good biomarker for OSCC
diagnosis.
El-Naggar
et al., 2001
Genetic heterogeneity in saliva from
patients with oral squamous
carcinomas: implications in
molecular diagnosis and screening
40 OSCC 10 DNA
microsatellite
Diagnosis A correlation on DNA microsatellite alterations between
saliva and tumor specimens was found. The saliva ctDNA
can be used as a genetic biomarker for early detection of
OSCC.
Viet and
Schmidt,
2008
Methylation array analysis of
preoperative and postoperative
saliva DNA in oral cancer patients
13 OSCC 10 DNA
hypermethylation
Diagnosis
and
prognosis
Sites highly methylated in the tissue and preoperative
saliva samples, but not methylated in the postoperative
saliva samples or in normal subjects, were found.
A genetic classifier consisting of specifically methylated
gene loci was generated and can be used as a composite
biomarker for early diagnosis and prognosis of OSCC.
Sethi et al.,
2009
Non-invasive molecular detection of
head and neck squamous cell
carcinoma: an exploratory analysis
27 HNSCC
(7 OSCC)
10 CNV (loss and
gain)
Diagnosis Gain of PMAIP1 (18q21.31) solely or in conjunction with
gain of PTPN1 (20q13.13), detected in saliva DNA,
differentiated 100% of HNSCC cases from normal
controls with high sensitivity and specificity, with no tumor
site differentiation. However, it has clinical utility for
non-invasive HNSCC diagnosis and screening, including
OSCC.
Demokan
et al., 2010
KIF1A and EDNRB are differentially
methylated in primary HNSCC and
salivary rinses
101
HNSCC (39
OSCC)
76 DNA
hypermethylation
Diagnosis Promoter hypermethylation of K1F1A and EDNRB genes,
detected in saliva DNA, is preferentially methylated in
salivary rinses from HNSCC compared with healthy
patients. In addition, patients with OSCC had higher
methylation on the K1F1A promoter. KIF1A and EDNRB
are potential biomarkers for HNSCC detection, with
K1F1A being more specific for OSCC.
Carvalho
et al., 2011
Detection of promoter
hypermethylation in salivary rinses
as a biomarker for head and neck
squamous cell carcinoma
surveillance
61 HNSCC
(30 OSCC)
– DNA
hypermethylation
Prognosis
and follow-up
Of the HNSCC patients analyzed, 54.1% showed
methylation in the promoter of at least one of the studied
genes (i.e., DAPK, DCC, MINT-31, TIMP3, p16, MGMT,
and CCNA1) in saliva ctDNA, with a significantly lower
local disease control and overall survival in patients with
recurrence. In addition, among all sites analyzed, a higher
percentage of patients with OSCC, with respect to the
other sites, showed DNA hypermethylation. Detection of
DNA hypermethylation in saliva ctDNA can potentially
predict local recurrence and overall survival in OSCC
patients.
Guerrero-
Preston et al.,
2011
NID2 and HOXA9 promoter
hypermethylation as biomarkers for
prevention and early detection in
oral cavity squamous cell
carcinoma tissues and saliva
16 OSCC 19 DNA
hypermethylation
Diagnosis The promoter hypermethylation of HOXA9 and NID2
genes detected in tissue, saliva, and serum ctDNA of
OSCC patients has a moderate to significant agreement
with clinical diagnosis, distinguishing healthy from OSCC
patients at the moment of pretreatment. They are
potentially useful for OC early detection and prevention.
Sun et al.,
2012
Detection of TIMP3 promoter
hypermethylation in salivary rinse as
an independent predictor of local
recurrence-free survival in head and
neck cancer
197
HNSCC (53
OSCC)
– DNA
hypermethylation
Prognosis Promoter hypermethylation of TIMP3 detected in
pretreatment salivary rinse ctDNA of HNSCC patients is
associated with disease-free survival; even if without
tumor site differentiation, hypermethylation of TIMP3 can
be considered a salivary independent prognostic factor of
HNSCC recurrence, including OSCC.
Rettori et al.,
2013
Prognostic significance of TIMP3
hypermethylation in post-treatment
salivary rinse from head and neck
squamous cell carcinoma patients
146
HNSCC (70
OSCC)
60 DNA
hypermethylation
Diagnosis,
prognosis,
and follow-up
DNA hypermethylation in CCNA1, DAPK, DCC, MGMT,
and TIMP3 is strictly correlated to the presence of OSCC
tumor. Moreover, 100% of HNSCC patients with TIMP3
DNA hypermethylation, 6 months after treatment, had
lower local recurrence-free survival. DNA
hypermethylation on CCNA1, DAPK, DCC, MGMT, and
TIMP3 genes is a specific OSCC diagnostic biomarker;
TIMP3 DNA hypermethylation is an independent
prognostic factor to recognize HNSCC patient subgroups
with high risk of local recurrence.
(Continued)
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TABLE 1 | Continued
Authors
(year)
Title Cases Controls Type of
alteration
Application Results
Ramadoss
et al., 2015
C-deletion in exon 4 codon 63 of
p53 gene as a molecular marker for
oral squamous cell carcinoma: a
preliminary study
20 OSCC 5 DNA point
mutation
Diagnosis PCR data showed the presence of C-deletion in exon 4 of
p53 gene in saliva of 100% OSCC. Mutation in exon 4
codon 63 of the p53 gene, evaluated by PCR, is a fast,
reliable, accurate, and sensitive molecular method that may
be employed as a potential molecular diagnostic marker for
OSCC.
Wang et al.,
2015
Detection of somatic mutations and
HPV in the saliva and plasma of
patients with head and neck
squamous cell carcinomas
93
HNSCC
(3 OSCC)
– DNA somatic
mutations and
HPV genes
Diagnosis,
prognosis,
and follow-up
After evaluation of ctDNA somatic mutations or HPV genes
from saliva and plasma of HNSCC patients, saliva ctDNA
mutations resulted in 100% specificity for OSCC cancer
detection. Moreover, any mutation was identified after
surgery in the patients whose tumors did not recur, being
considered a valuable diagnostic, prognostic, and follow-up
biomarker.
Ferlazzo
et al., 2017
Influence of MTHFR genetic
background on p16 and MGMT
methylation in oral squamous cell
cancer
58 OSCC 90 DNA
hypermethylation
Diagnosis There is a higher frequency of p16 and MGMT promoter
methylation in OSCC patients than in normal controls. The
assessment of DNA methylation rate could represent a
powerful diagnostic approach for early detection of cancer.
Lacombe
et al., 2017
Analysis of saliva gene expression
during head and neck cancer
radiotherapy: a pilot study
8 HNSCC
(1 OSCC)
– Aberrant
expression
Follow-up This pilot study shows that salivary gene biomarkers can be
detected and their expression modified during head and
neck radiotherapy. The increasing expression of the genes
CCDKN1A and DDB2, during radiation treatment, is
correlated to the cumulative received dose. Saliva is a
minimally invasive means of biomarker collection to directly
measure radiation dose escalation during treatment.
OSCC, oral squamous cell carcinoma; ctDNA, circulating tumor DNA; TSG, tumor suppressor gene; HNSCC, head and neck squamous cell carcinoma; CNV, copy
number variation; miRNA, microRNA; PCR, polymerase chain reaction; HPV, human papillomaviruses; MTHFR, methylenetetrahydrofolate reductase.
TABLE 2 | Diagnostic and prognostic application of EVs in OSCC, based on population study.
Authors (year) Title Cases Controls Type of alteration Application Results
Winck et al.,
2015
Insights into immune responses
in oral cancer through
proteomic analysis of saliva and
salivary extracellular vesicles
24 OSCC 10 Aberrant expression Prognosis The proteomic data from whole saliva and
saliva EVs of OSCC and healthy patients allow
us to classify OSCC patients with 90%
accuracy, being considered valuable additional
parameters/biological biomarkers to define the
prognosis in OSCC patients.
Zlotogorski-
Hurvitz et al.,
2016
Morphological and molecular
features of oral fluid-derived
exosomes: oral cancer patients
versus healthy individuals
36 OC (OSCC
not specified)
25 Altered exosome
morphology and
protein composition
Diagnosis Saliva from OC patients contains
morphologically and molecularly different
exosomes with respect to healthy subjects. In
particular, the decrease in the expression of
CD9 and CD81 rather than the increase of
CD63 expression can be an indicator of OC,
even in the very early stages of the disease, in
high-risk patients without clear clinical sign.
EV, extracellular vesicle; OC, oral cancer; OSCC, oral squamous cell carcinoma.
MicroRNAs can be released into body fluids as cell-
free miRNAs, associated with RNA-binding proteins or
selectively packaged into EVs (Larrea et al., 2016). Their
involvement in tumor microenvironments has been widely
investigated, demonstrating that the expression of miRNAs
could be associated with the deregulation of oncosuppressors or
oncogenes, contributing to tumor development or inhibition.
Moreover, they were unchanged in tissues and body fluids,
and their expression is frequently tumor specific; for these
reasons, the possibility to analyze miRNA profiles associated
with cancer patients represents a new paradigm in biomarker
discovery for cancer clinical diagnostics. Specifically, with
regard to HNSCC cancers strictly associated with saliva,
the evaluation of miRNAs released by OSCC cells in saliva
represents a promising perspective for OSCC management
(Momen-Heravi et al., 2014).
Over the years, many studies and reviews summarized the
updates on evaluation of miRNA expression alteration for
diagnosis and risk stratification of oral cancers, finding that
many miRNAs are differentially expressed between healthy and
OSCC patients (Table 3; Park et al., 2009; Wiklund et al.,
2011; Liu et al., 2012; Yang et al., 2013; Momen-Heravi et al.,
2014; Al-malkey and Abbas, 2015; Zahran et al., 2015; Duz
et al., 2016; Greither et al., 2017). The different salivary
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TABLE 3 | Diagnostic and follow-up application of miRNAs in OSCC, based on population study.
Authors (year) Title Cases Controls Type of alteration Application Results
Park et al.,
2009
Salivary microRNA: discovery,
characterization, and clinical
utility for oral cancer detection
10 OSCC 10 Expression
downregulation
Diagnosis miRNAs are present in both whole saliva and
supernatant saliva. Two of evaluated miRNAs,
miR-125a and miR-200a, are downregulated in the
saliva of the OSCC patients compared to healthy
controls, being useful in detecting OSCC.
Wiklund et al.,
2011
MicroRNA alterations and
associated aberrant DNA
methylation patterns across
multiple sample types in oral
squamous cell carcinoma
15 OSCC 7 Aberrant
expression and
DNA
hypermethylation
Diagnosis Compared to healthy subjects, OSCC patients had
deregulated miRNAs with associated DNA
methylation patterns. Particularly, repression of
miR-375 and methylation on miR-137,
miR-200c-141, and miR-200 s/miR-205 loci were
found in OSCC patients vs. healthy patients, being
promising candidates to develop OSCC-specific
miRNA signatures.
Liu et al., 2012 Exploiting salivary miR-31 as a
clinical biomarker of oral
squamous cell carcinoma
45 OSCC 24 Expression
upregulation
Diagnosis and
follow-up
Salivary miR-31 was significantly increased in
patients with OSCC at all clinical stages, including
very early stages. In addition, it was shown to be
more abundant in saliva than in plasma, and after
tumor surgical removal, its expression was
reduced. Salivary miR-31 is a promising specific
biomarker for early detection and postoperative
follow-up of OSCC.
Yang et al.,
2013
Progress risk assessment of
oral premalignant lesions with
saliva miRNA analysis
45 OSCC
potentially
progressing
LGD
leukoplakia
- Aberrant
expression
Diagnosis A specific miRNA aberrant profile was found in
saliva samples of progressing oral LGD leukoplakia;
it allows monitoring of cancer precursor lesions and
early detection of progression toward OSCC,
before clinical evidence.
Momen-Heravi
et al., 2014
Genomewide study of salivary
microRNAs for detection of oral
cancer
9 OSCC-bt, 8
OSCC-r
9 Aberrant
expression
Diagnosis The miRNA profiles derived from OSCC, OSCC-r,
and healthy controls were distinctively different. In
particular, overexpression of miRNA-27b was found
in OSCC saliva samples and not in the saliva of the
other two groups; it can be potentially considered a
promising OSCC diagnosis salivary biomarker.
Zahran et al.,
2015
Salivary microRNAs in oral
cancer
100 OC (20
OSCC)
20 Aberrant
expression
Diagnosis Salivary miRNA-21, miRNA-145, and miRNA-184
were differentially expressed in OSCC and healthy
saliva samples. They can be considered
non-invasive, rapid diagnostic biomarkers for oral
malignant transformation and early detection of
OSCC, with miRNA-184 having the best diagnostic
value.
Al-malkey and
Abbas, 2015
Expression analysis of salivary
microrna-31 in oral cancer
patients
35 OC (OSCC
not specified)
20 Expression
upregulation
Diagnosis and
follow-up
Salivary miR-31 expression increased in OC
patients, with enrichment in saliva compared with
plasma, allowing the proposal of miR-31 as a
sensitive biomarker for early detection and
postsurgical follow-up of OC.
Duz et al., 2016 Identification of miR-139-5p as
a saliva biomarker for tongue
squamous cell carcinoma: a
pilot study
25 OSCC 25 Aberrant
expression
Diagnosis Salivary miR-139-5p was significantly reduced in
TSCC patients compared to controls, and its level
turned back to normal after surgery. It is a feasible
and promising diagnostic marker.
Greither et al.,
2017
Salivary miR-93 and miR-200a
as post-radiotherapy
biomarkers in head and neck
squamous cell carcinoma
17 HNSCC (5
OSCC)
– Aberrant
expression
Follow-up MiR-93 and miR-200a were significantly increased
12 months after radiotherapy, demonstrating to be
valuable biomarkers for treatment monitoring
post-radiation of HNSCC.
miRNA, microRNA; LGD, low-grade dysplasia; OSCC, oral squamous cell carcinoma; OSCC-bt, oral cancer cell carcinoma before treatment; OSCC-r, oral cancer cell
carcinoma in remission; OC, oral cancer; TSCC, tongue squamous cell carcinoma.
expression of miRNAs, as miR-125, miR- 200a, miR-21, miR-
145, miR-200a, miR-93, miR-375, and miR-184 in OSCC patients
compared to the healthy subjects, has been demonstrated to be
a reliable method to detect OSCC and potentially malignant
oral lesions (Park et al., 2009; Wiklund et al., 2011; Zahran
et al., 2015; Greither et al., 2017; Maheswari et al., 2018).
Salivary miR-139-5p has also demonstrated to be a valuable
biomarker for response to therapy and evaluation of OSCC
recurrence; it was downregulated in saliva samples from OSCC
patients compared to the saliva of healthy subjects, and its
expression increased in OSCC patient saliva after surgery
(Duz et al., 2016).
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Finally, other studies also focused on the potential of
salivary miRNAs to assess the progression risk of oral
premalignant lesions to OSCC, distinguishing progressing from
non-progressing oral low-grade dysplasia; for example, the
increased expression of miR-708, miR-10b, miR-19a, miR-
30e, miR-26a, and miR-660 and decreased expression of miR-
99, miR-15a, miR-197, miR-145, and miR-150 in saliva of
OSCC patients represent biomarkers for neoplastic malignant
transformation of oral lesions as oral low-grade dysplasia; some
miRNAs, notably acting in cancer as oncosuppressors and
found upregulated in patients with oral low-grade dysplasia,
could represent elements of protection against the malignant
transformation (Yang et al., 2013). Even though current
evidence on the role of miRNAs in OSCC is encouraging,
it is suggested that a combination of salivary miRNAs
and proteomic data could help to have greater coverage
and increased robustness of results (Yakob et al., 2014;
Zahran et al., 2015).
Other Potential Biomarkers: CTCs
Circulating tumor cells have been widely investigated in the
bloodstream as other potential OSCC biomarkers. They are
released from primary tumor mass, disseminating via the
lymphatic and blood vessels throughout the body. Their presence
in blood circulation is correlated to metastasis, recurrences, and
worse prognosis (Jatana et al., 2010; Hristozova et al., 2011;
Alix-Panabier´es and Pantel, 2013; Grobe et al., 2013). They can
both promote the development of metastasis and colonize the
primary tumor site, supporting the primary tumor growth in
a process called tumor self-seeding (Ilie et al., 2014; Zhang
et al., 2016). Many studies highlighted the correlation between
increased levels of CTCs and OSCC diagnosis (Nichols et al.,
2012; He et al., 2013); however, it seems that the increased
number of CTCs is more correlated to prognosis and locoregional
relapse (Jatana et al., 2011; Buglione et al., 2012; Gröbe et al.,
2014). Therefore, analysis of CTCs in blood samples of cancer
patients may really support clinician decisions, helping to
phenotypically and genetically characterize the primary tumor
(Jatana et al., 2010; Ilie et al., 2014; Lianidou et al., 2014;
Rolfo et al., 2014; Tinhofer et al., 2014; Wu et al., 2016; Zhou
et al., 2016), but being more frequently found in late-stage
cancers, it seems to be more informative as a tool for cancer
prognosis; moreover, the investigation of drug molecular targets
on the CTC surface could help to develop immunotherapies
(Nonaka and Wong, 2018). All studies performed so far derived
from analysis of blood samples; the investigation of CTC on
saliva remains unexplored. We conceive that future studies
on salivary CTCs from OSCC patients may provide relevant
information about tumor prognosis and genetic alterations
potentially associated with tumor recurrence, contributing to
development of targeted therapies.
DISCUSSION
With a frequency of 2–4% of all worldwide cancer cases,
OSCC is the most common epithelial neoplasia affecting
the head-and-neck area (Markopoulos, 2012). Many efforts
have been done so far to improve the strategies of OSCC
diagnosis, prognosis, and development of therapies; however,
it still is a cancer with poor prognosis (Moore et al., 2000).
This primarily depends on diagnostic delay and insufficiently
informative techniques to do prognosis and uncover tumor
recurrence after surgery and/or therapy establishment.
Given the intra-tumoral and inter-tumoral heterogeneity
and the dynamic behavior with modification over time on
the molecular profile, also depending on the therapeutical
response, the traditional strategies of cancer screening are
not sufficient for the effective management of OSCC; we
urgently need novel and more effective time-saving strategies
(Bellairs et al., 2017). In light of the above, the latest body of
literature has focused on understanding the tumor-leading
molecular basis, to develop more precise and advanced
methodologies for early detection, prognosis, and establishment
of successful therapies, decreasing the rate of recurrences
(Woolgar, 2006).
Liquid biopsy is currently one of the most investigated
techniques to easily outline the molecular identity of cancers in
both early and late stages, and due to its accessibility, ease of
employment, and natural feature of being in close contact with
OSCC cells, saliva is considered one of the most indicative body
fluids for liquid biopsy in OSCC (Kaczor-Urbanowicz et al., 2017;
Gai et al., 2018; Khurshid et al., 2018).
Saliva has been proposed as a valuable means for early
diagnosis, definition of cancer patient molecular profile, and
development of a personalized therapy and allows monitoring
of response and cancer relapse; indeed, it contains bioactive
elements such as ctDNAs, miRNAs, and EVs derived from OSCC
cells, where genetic and epigenetic alterations can be easily
detected and give relevant information. In particular, salivary
ctDNA, miRNAs, and EVs seem to be the preferred biomarkers
for early detection and diagnosis; instead, CTCs, even if more
widely investigated in plasma, seem to be more informative to
predict prognosis (Nonaka and Wong, 2018).
The results obtained so far lead to the term “salivaomics”
to indicate all the translational and clinical tools based on
salivary biomarkers and considered very supportive for cancer
management (Wong, 2014).
CONCLUSION AND FUTURE
PERSPECTIVES
There is an increasing interest in employing saliva samples as a
source of biomarkers for OSCC liquid biopsy analysis. However,
there are still several challenges that are yet to be overcome which
are briefly indicated below and summarized in Table 4 for each of
the mentioned and revised biomarkers.
ctDNA
Salivary ctDNA holds cancer DNA genetic and epigenetic
alterations; it can reflect the complex molecular profile deriving
from tumor spatial and intratumoral heterogeneity, and its
alterations in sequence can primarily support diagnosis and
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TABLE 4 | Pros and cons of salivary biomarkers in OSCC diagnosis, prognosis
and follow-up.
Salivary
biomarkers
Pros Cons
ctDNA • ctDNA holds cancer DNA
genetic and epigenetic
alterations
• Inter-patient (e.g., age, gender,
diet, and smoking) and
intra-patient variability and
tumoral and temporal
heterogeneity
• Non-tumoral circulating free
DNA contamination of sample
• ctDNA can reflect the complex
molecular profile deriving from
tumor spatial and intratumoral
heterogeneity
• High costs of isolation and
detection technologies (e.g.,
NGS and RT-qPCR)
• DNA alterations in ctDNA
and/or relative levels are useful
for cancer diagnosis,
prognosis, and follow-up
• Little coverage of ctDNA
alteration detection platform
• No standardized and
reproducible protocols
EVs • EVs allow detection of
low-expression biomarkers
otherwise not detectable in
saliva
• Complex and expensive
isolation (i.e.,
ultracentrifugation,
ExoQuick-TC, and an aqueous
two-phase system),
characterization (e.g., electron
microscopy, dynamic light
scattering, and western
blotting), and analysis
technologies (e.g., RT-qPCR)
• EV different relative levels,
morphology, and composition
(e.g., lipids, proteins, DNA, and
miRNAs) are useful for cancer
diagnosis and prognosis
• No standardized and
reproducible protocols
miRNAs • The aberrant expression of
miRNAs is informative for
cancer diagnosis and follow-up
• Expensive detection and
analysis (e.g., RT-qPCR)
technologies
• Absence of valid endogenous
RT-qPCR control
• Inter-patient variability (e.g.,
age and inflammation)
• No standardized and
reproducible protocols
ctDNA, circulating tumor DNA; EV, extracellular vesicle; miRNA, microRNA; NGS,
next-generation sequencing; OSCC, oral squamous cell carcinoma; RT-qPCR,
quantitative reverse-transcription PCR.
secondly prognosis and assessment of patient response to
therapy; nevertheless, several challenges still need to be overcome
for ctDNA implementation in clinics (Van Ginkel et al., 2017;
Payne et al., 2018). Firstly, it is necessary to improve the ctDNA
isolation methodologies and sensibility of detection technologies
to remove the noise due to cfDNA molecules physiologically
released from non-tumoral cells and detect cancer even in
the presence of an almost undetectable amount of ctDNA. In
addition, we need to reduce the bias derived from inter-patient
(e.g., age, gender, diet, and smoking) and intra-patient variability
and tumoral and temporal heterogeneity, for a higher specificity
of analysis, and it is necessary to improve the genetic coverage of
ctDNA detection platforms to detect multiple molecular markers
(Ignatiadis et al., 2015).
EVs
Extracellular vesicles allow detection of low-expression
biomarkers, and the relative levels, morphology, and composition
(e.g., lipids, proteins, and nucleic acids) were informative for
oral cancer diagnosis and prognosis. Nevertheless, the use
of EVs in OSCC management still has limitations related to
the complex and expensive isolation, characterization, and
analysis technologies. Among all methods to isolate salivary
EVs, ultracentrifugation and ExoQuick-TC (a chemical-
based agent kit used to precipitate EVs) represent the most
currently physical-based used methods. Ultracentrifugation is
a widely used isolation methodology able to give a minimally
contaminated EV pellet; however, it is a complex and prolonged
process that needs specialized and expensive equipment as well
as large samples. In contrast, ExoQuick-TC can isolate and
purify EVs from small samples, even if with more impurities
compared to ultracentrifugation (Théry et al., 2006; Zlotogorski-
Hurvitz et al., 2015; Boriachek et al., 2018). Another technique
to isolate salivary EVs, named the aqueous two-phase system,
has been recently developed by Kim et al. (2017) and seems
to be more efficient in terms of yield and purity compared
to ultracentrifugation and ExoQuick-TC. With regard to
characterization, the following techniques are worth mentioning:
electron microscopy; an ultra-sensitive technique of low-force
microscopy to investigate shape, structure, chemistry, and
mechanics of vesicles; dynamic light scattering to perform
a size distribution analysis; and western blotting analysis to
evaluate EV-specific markers (Théry et al., 2006; Byun et al.,
2015). However, despite their widespread use in daily laboratory
activity, the above-described techniques are still too expensive
and time-consuming to employ in clinical routine. The use of size
and surface markers for selection is urgently necessary to increase
yield and quality of isolated vesicles (Witwer, 2015; Barger et al.,
2016); besides, the development of new and innovative strategies
is essential to more easily characterize EVs. Last, but not least,
the validation and standardization of protocols are essential to
safely move from the bench to the bedside; develop an easy, cost-
effective, and robust clinical strategy; and obtain reproducible
data (Witwer et al., 2013; Zahran et al., 2015; Han et al., 2018).
MiRNAs
The aberrant expression of miRNAs is very supportive of
OSCC diagnosis, but as previously described for other salivary
biomarkers, we still need to face many challenges. The protocols
used to analyze and quantify isolated miRNAs need to be
normalized and standardized. In the case of RT-qPCR analysis,
global mean expression and exogenous (spiked-in) miRNAs and
endogenous controls are currently used to normalize RNAs
(Mestdagh et al., 2009; Yoshizawa and Wong, 2013). Current
research identified miR-191 and miR-16 as unique suitable
endogenous controls; however, they need to be validated in larger
cohorts of patients (Momen-Heravi et al., 2014). Another variable
that influences miRNA investigation in OSCC is the inter-
patient variability (e.g., age and inflammation). Age represents
Frontiers in Physiology | www.frontiersin.org 8 December 2019 | Volume 10 | Article 1476
fphys-10-01476 December 6, 2019 Time: 18:11 # 9
Cristaldi et al. Saliva for Oral Cancer Management
a continuous variable affecting the investigations; many studies
demonstrate that miRNAs are involved in the regulation of aging
processes and are often upregulated in older individuals. This
may be limiting and decrease the robustness, sensitivity, and
specificity of miRNA investigation in OSCC patients (Wan et al.,
2017). Inflammation is a typical condition of cancer development
and influences the expression of miRNAs; possible fluctuations
of miRNA expression may not be directly linked to cancer
features, but to body inflammatory response to cancer presence,
perturbing miRNA expression and decreasing reproducibility of
data (Kulkarni et al., 2017). Standardization of protocols should
be defined to store and handle isolated miRNAs, making them
available for clinical routine (Witwer et al., 2013).
CONCLUSION
In line with the current status and perspectives of liquid biopsy
and saliva analysis, saliva has promising implications in OSCC
management; it is conceivable that future studies on employment
of ctDNAs, EVs, miRNAs, and CTCs, as salivary biomarkers in
OSCC clinical routine, will certainly help to establish consistent
strategies for early diagnosis of cancer lesions, facilitate advance
prevention, and support the development of targeted therapies;
this will improve treatment outcomes of OSCC patients, also
reducing chemotherapy/radiotherapy side effects.
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